B2B model for commercializing research outcomes and intellectual property through partner companies
First written in FY2022. 5 of 9 entries say "Advanced", first in FY2024-Q2. Latest entry: 2026-06-25.
No other company in this theme has enough history to compare yet.
- 2026-06-25ReframedManagement Planning
「Customers: primarily B2B; B2B + B2C」
The company indicates a growth stage in which the customer mix is shifting from primarily B2B to a combination of B2B and B2C. - FY2026AdvancedAnnual report
「As a new business, we concluded an exclusive distribution agreement in Japan and began sales of aeonia, a basic cosmetics brand developed by U.S.-based Delavie Sciences based on research at Harvard University.」
A new commercialization example has been added to the B2B model of bringing research results and products from external partners to market through corporate agreements: the launch of exclusive domestic sales of aeonia. - FY2026-H1AdvancedAnnual report
「Discussions are also actively under way with prospective international partners regarding the new drug pipelines TLM-017 and TLM-023.」
Commercialization discussions with prospective international partners for the new drug pipelines TLM-017 and TLM-023 are progressing. - FY2025-H1AdvancedAnnual report
「In September, the company entered into a patent license agreement covering specific regions with Shenyang Xingqi Pharmaceutical Co., Ltd., a major Chinese ophthalmic pharmaceutical manufacturer.」
The company granted a patent license to a Chinese ophthalmic pharmaceutical manufacturer, expanding the target regions for its B2B model of providing intellectual property and treatments through partner companies. - FY2024-Q2AdvancedAnnual report
「Under a patent implementation and use license agreement with NEC Personal Computer Co., Ltd., the company launched personal computers equipped with violet-light LEDs.」
An additional example has been provided of the B2B model in which a partner company launches products incorporating the company’s technology and commercializes research results and intellectual property through the partner. - FY2023RestatedAnnual report
「Because the company has no direct contact with patients, its direct customers are major companies that interact with patients, the end users, making this a B2B business model.」
The company has reconfirmed its B2B structure of delivering research results and intellectual property to end users through major partner companies. - FY2022First statedAnnual report
「The company has no direct contact with patients, and its direct customers are major companies that have channels to the end users, who are patients, making this a B2B business model.」
The structure commercializes university science and delivers it to end users through major companies.